Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lens surface protein deposits are accumulations of tear film components—primarily proteins like lysozyme, lipocalin, lactoferrin, albumin, and IgA—alongside mucins, lipids, calcium, and environmental contaminants on the anterior (and occasionally posterior) surfaces or within the matrix of contact lenses. These deposits form rapidly upon lens insertion and are encouraged by factors such as lens material, surface charge, and hydrophilicity. The deposits can denature, losing normal protein structure and function, leading to impaired lens clarity, reduced antimicrobial protection, ocular irritation, and inflammation. Clinical symptoms include discomfort, dryness, blurred vision, and a higher risk of ocular complications. Removal methods involve chemical cleaning solutions, enzymatic digestion, physical rubbing, and, most recently, electrophoresis. Unlike true molecular targets, lens surface protein deposits represent a pathology associated with medical devices rather than a specific molecular entity.
Physical/chemical removal—detergent, enzymatic digestion (e.g., proteases), chelating agents, electrophoresis[3][5][6]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lens surface protein deposit.